Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, double-blind, triple-dummy, placebo controlled, multicenter, 5-period, single-dose complete block crossover study to determine the onset of action of indacaterol (150 and 300 microg) in patients with moderate to severe COPD [chronic obstructive pulmonary disease] using salbutamol (200 microg) and salmeterol/fluticasone (50/500 microg) as active controls.

Next Previous
Trial Profile

A phase III, randomized, double-blind, triple-dummy, placebo controlled, multicenter, 5-period, single-dose complete block crossover study to determine the onset of action of indacaterol (150 and 300 microg) in patients with moderate to severe COPD [chronic obstructive pulmonary disease] using salbutamol (200 microg) and salmeterol/fluticasone (50/500 microg) as active controls.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Salbutamol; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 12 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009).
  • 12 Sep 2009 Status changed from recruiting to completed.
  • 26 May 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top